Inventiva Investor Relations Material

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of orally administered small molecule therapies for the treatment of serious diseases. The company's research primarily targets conditions related to fibrosis, lysosomal storage disorders, and oncology. Inventiva leverages its proprietary technology platform to identify and develop novel compounds that modulate nuclear receptors, transcription factors, and epigenetic regulation. The company's lead products are developed through strategic collaborations with other pharmaceutical companies, aiming to advance these therapies through clinical trials and regulatory approval. The company is headquartered in Daix, France, and its shares are listed on the Nasdaq.